Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Temporary Codes for Use with Outpatient Prospective Payment System
C9098 is a valid 2023 HCPCS code for Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose or just “Ciltacabtagene car pos t” for short, used in Medical care.
HCPCS Level II Code Temporary Codes for Use with Outpatient Prospective Payment System |
|
HCPCS Code | C9098 |
---|---|
Description |
Long description:
Short description: |
HCPCS Modifier1 | |
HCPCS Pricing indicator |
53 - Statute
|
Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
Coverage code | C - Carrier judgment |
BETOS2 code | O1D - Chemotherapy |
HCPCS Action code | N - No maintenance for this code |
Type of service | 1 - Medical care |
Effective date | Effective Oct 01, 2022 |
Date added | Added Jul 01, 2022 |
Termination date | Sep 30, 2022 |
HCPCS Coding Procedures |
In HCPCS Level II, modifiers are composed of two alpha or alphanumeric characters.
Example: E0260-NU - Hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress
“NU” identifies the hospital bed as new equipment
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”